AstraZeneca & Merck announce OlympiA phase 3 trial of Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer: Rahway, New Jersey Friday, Dec ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

The London Cancer Hub is a collaboration between The Institute of Cancer Research, London, and the London Borough of Sutton, with the support of The Royal Marsden NHS Foundation Trust and the Greater ...

When Sue Vincent was diagnosed with advanced ovarian cancer, she was told she could have just months to live - until a miracle drug changed everything ...

The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

Dec. 5, 2024 — Mangroves have been shown to provide $855 billion in flood protection services worldwide, according to a new ... Dec. 4, 2024 — Coconut palms are king throughout the tropics ...

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast ...

Lynparza demonstrates sustained survival benefits in Phase III OlympiA breast cancer trial, reducing death risk by 28% over ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...